Startups
Edit
https://www.portalresearch.org/
Program On Regulation, Therapeutics, And Law
TrustedLast activity: 23.09.2026
Active
We're shaping the dialogue on how laws and regulations should best influence the development, use,
and affordability of prescription drugs and medical devices.
and affordability of prescription drugs and medical devices.
Overview
Location
United States, Massachusetts, Boston
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 10, 2019 | Do large pharma companies provide drug development innovation? Our analysis says no | Large pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug development and the discovery of new medic... |
| May 15, 2019 | Almost half of all new drug approvals in 2018 relied on one clinical trial | Back in the 1970s and 1980s, the FDA made clear that at least two adequate and well-controlled studies were necessary to establish a new drug’s effectiveness, except in only the rarest of circumstances. Then in 1997, the Food... |
| May 25, 2018 | FDA: Drugmaker ‘shenanigans’ delaying cheaper competitors and boosting prices | The FDA listed more than 50 drugs whose manufacturers have withheld or refused to sell samples, and cited 164 inquiries for help obtaining them. Thirteen of these pleas from makers of generics pertained to Celgene’s blockbuster cancer drug ... |
| May 18, 2017 | Clinical trial participants should have a say in new drug pricing | People who volunteer to participate in clinical trials of new drugs provide a valuable service to pharmaceutical companies and to the rest of us. In return, I think that they should have a say in how much these drugs will cost when they hit... |
| FDA: Drugmaker ‘shenanigans’ delaying cheaper competitors and boosting prices | Makers of brand-name drugs called out by the Trump administration for potentially stalling generic competition have hiked their prices by double-digit percentages since 2012 and cost Medicare and Medicaid nearly $12 billion in 2016, a Kaise... |
Reviews 0
FAQ about Program On Regulation, Therapeutics, And Law
What has the press written about Program On Regulation, Therapeutics, And Law?
Parsers VC has collected 6 articles mentioning Program On Regulation, Therapeutics, And Law, among them “Do large pharma companies provide drug development innovation? Our analysis says no” (Dec 10, 2019) and “Almost half of all new drug approvals in 2018 relied on one clinical trial” (May 15, 2019).
Is Program On Regulation, Therapeutics, And Law still active?
Yes, Program On Regulation, Therapeutics, And Law is active; its latest activity on Parsers VC dates from Sep 23, 2026.